Navigation Links
Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008
Date:7/9/2008

Most Surveyed MCO Pharmacy Directors Will Move Razadyne and Razadyne ER from Tier 2 to Tier 3 When Generic Razadyne is Launched, According to a New

Report from Decision Resources

WALTHAM, Mass., July 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic availability of Shire/Janssen/Ortho McNeil's Razadyne (galantamine) in December 2008 will have the greatest impact on Eisai/Pfizer's Aricept as surveyed primary care physicians (PCPs) estimate that after the launch of generic galantamine, prescriptions of Aricept for the treatment of Alzheimer's disease will drop by up to 20 percent. According to the new Physician & Payer Forum primary market research report entitled The Impact of Razadyne's Genericization and the Launch of Biologic Disease-Modifying Drugs on the Alzheimer's Disease Market: Clinician and Payer Receptivity to Novel Agents, the availability of generic galantamine will decrease Aricept's share of PCPs' prescriptions for Alzheimer's disease patients from 66 percent to 46 percent by December 2009. The report also finds that for surveyed neurologists, Aricept's share of prescriptions for Alzheimer's disease patients will fall from 62 percent to 44 percent.

According to the report, more than two-thirds of managed care organizations (MCOs) that cover Razadyne and Razadyne ER in their private plan formularies grant these agents tier 2 status. When generic galantamine becomes available, many surveyed MCO pharmacy directors indicated that they will move both Razadyne formulations to tier 3. Additionally, nearly one quarter of surveyed MCO pharmacy directors said they will remove Razadyne ER from their private plan formularies, and more than one third will remove Razadyne, when generic galantamine becomes available. The percentage of pharmacy directors who reported they will remove Razadyne ER and Razadyne from their Medicare prescription drug plan formularies was slightly lower.

The report also finds that clinicians do not have clear expectations of disease-modifying agents for Alzheimer's disease. Three quarters of surveyed clinicians favor an oral formulation over an intravenous formulation of a disease-modifying agent for Alzheimer's because of convenience. Thirty three percent of PCPs versus 21 percent of neurologists would select a regimen with lowest out-of-pocket costs for patients. In terms of patient compliance, 15 percent of neurologists compared with 11 percent of PCPs would select an intravenous regimen over an oral formulation.

"While clinicians anticipate prescribing Aricept less frequently when generic galantamine becomes available, this trend will not be accelerated by a widespread shift of Aricept to unfavorable formulary tiers," said Andrea Witt, Ph.D., director at Decision Resources. "MCO pharmacy directors indicate that Aricept will still enjoy favorable tier status on most private and Medicare prescription drug plans after the launch of generic galantamine."

The Impact of Razadyne's Genericization and the Launch of Biologic Disease-Modifying Drugs on the Alzheimer's Disease Market: Clinician and Payer Receptivity to Novel Agents is based on a U.S. survey of 71 neurologists, 72 PCPs and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Study finds primary care depression treatment often does not follow quality guidelines
3. Primary biliary cirrhosis more severe in African-American and Hispanic patients
4. New research may lead to earlier diagnosis and treatment of primary biliary cirrhosis in families
5. Revisions to College Cost Reduction and Access Act will create barriers to primary care
6. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
7. Editorial says primary care system must change how it approaches dementia
8. S&P: Leverage Tops Politics as Primary Credit Concern for U.S. Health Care Companies, Says S&P
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. Visual field loss primary component in risk of falls for older adults
11. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a ... problem. A common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated ... orthopedic spine surgeon at Atlantic Spine Center . , So named because ...
(Date:5/24/2016)... ... 24, 2016 , ... Researchers from Catholic Health Initiatives (CHI) ... bleeding complications from percutaneous coronary intervention (PCI). The data, presented at the annual ... document a 40% reduction in risk-adjusted bleeding event rates over a two-year period ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... web-based software module. The cutting-edge feature provides end users with an embedded, ... self-service business intelligence solution and its analytics engine. , This powerful ...
(Date:5/23/2016)... Akron, Ohio (PRWEB) , ... May 23, 2016 ... ... not-for-profit continuing care retirement community, dedicated its new $11.5 million, 64-room assisted living ... an invitation-only ceremony and ribbon cutting. , The new building provides the ...
(Date:5/23/2016)... ... May 23, 2016 , ... According to an article ... than 1% of United Kingdom residents who could benefit from bariatric surgery are actually ... increases the number of bariatric procedures it offers to obese patients from 6,000 to ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... 19, 2016 A new report ... Market -Opportunities and Forecasts, 2015 -2022, projects that the ... 2022, registering a CAGR of 5.1% from 2015 to ... be the highest revenue-generating segment throughout the forecast period. ... one-third of the market share in 2015, and is ...
(Date:5/19/2016)... -- The equities market is never short of ... is without doubt the Healthcare space. ActiveWallSt.com has uncovered four ... Alkermes PLC (NASDAQ: ALKS ), AMAG Pharmaceuticals Inc. ... IDXX ), and Atossa Genetics Inc. (NASDAQ: ... http://www.activewallst.com/ On Wednesday, Alkermes PLC,s ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology: